Key result
SGLT-2i therapy in hospitalized HF is linked to ~3.6-fold lower risk of readmission.
Why the study?
Heart failure represents a major and growing public health burden in France due to high costs and frequent rehospitalizations, prompting this evaluation of the impact of SGLT-2i on morbidity and rehospitalization in patients with HF.
Does treatment with sodium glucose cotransporter-2 inhibitors reduce heart failure-related hospital readmissions in patients hospitalized for heart failure?
Observational (n=160)
No
Does treatment with sodium glucose cotransporter-2 inhibitors reduce heart failure-related hospital readmissions in patients hospitalized for heart failure?
Answers are grounded in this paper and cite their sources.
In this single-center French retrospective cohort, SGLT-2 inhibitor use was associated with a markedly lower rate of heart failure readmissions (17% vs 70.5%), reinforcing real-world effectiveness in heart failure management.
Context and objective. Heart failure (HF) represents a major and growing public health burden in developed countries, including France, due to its high associated costs and frequent rehospitalizations. This study aimed to evaluate the impact of Sodium Glucose Cotransporter-2 Inhibitors (SGLT-2i) on morbidity and rehospitalization in patients with HF. Methods. We conducted a retrospective and descriptive case series study at the Sud Francilien Hospital Center from January 1, 2020, to December 31, 2023. We collected comprehensive data on sociodemographics, clinical characteristics (medical history and HF specifics), laboratory markers, echocardiographic findings, and treatement details to assesses whether SGLT-2i use was associated with a reduction in HF-related hospital readmissions. Results. Among the 160 patients (mean age 71 ± 16 years) hospitalized for HF, 95 (59.4%) did not receive SGLT-2i, and 67 (70.5%) of them were readmitted. Out of 65 patients treated with gliflozins, only 11 (17%) were readmitted. The use of SGLT-2i inhibitors was associated with a reduction in hospitalizations. Not receiving SGLT-2 inhibitors increased the risk of readmission by 3.6-fold (95% CI : 1.87-6,83, p<0 .001), emerging as the sole independent factor associated to heart failure readmission in this cohort. Conclusion. The introduction of SGLT-2i has been associated with improved outcomes and reduced rehospitalizations in HF management at our center. Further studies are needed to evaluate their impact on mortality. Contexte et objectif. L’insuffisance cardiaque (IC) est en constante augmentation dans les pays développés, notamment en France, et représente un problème majeur de santé publique en raison de son coût et du taux élevé de réhospitalisations. L’objectif de la présente étude était de déterminer les bénéfices des inhibiteurs du co-transporteur sodium-glucose de type 2 (SGLT-2i) sur la morbidité et les rehospitalisations chez les patients atteints d’IC. Méthodes. Une série rétrospective et descriptive des cas d’IC, a été menée du 1er janvier 2020 au 31 décembre 2023 au CH Sud Francilien. L’étude a recueilli des données exhaustives sur des facteurs sociodémographiques, cliniques (l’âge, le sexe, les habitudes de vie, les antécédents médicaux et les spécificités de l’IC), les marqueurs biologiques, les données échocardiographiques et les détails thérapeutiques (les types de médicaments et les effets indésirables des SGLT-2i). Résultats. Parmi les 160 patients âgés de 71 ± 16 ans admis pour IC, 95 (59,4 %) n’ont pas reçu d’inhibiteur du SGLT-2, et 67 (70,5 %) d’entre eux ont été hospitalisés. Parmi les 65 patients sous gliflozines, seuls 11 (17 %) ont été rehospitalisés. L’utilisation d’inhibiteurs du SGLT-2 était associée à une réduction du nombre d’hospitalisations. L’absence de prise des SGLT-2 augmente le risque de rehospitalisation de 3,6 (IC 95% : 1,87-6,83, p<0,001); émergeant comme seul unique facteur indépendamment associé à la rehospitalisation pour l’IC. Conclusion. Les inhibiteurs du SGLT-2 ont significativement amelioré la prise en charge de l’IC et représente l’unique facteur de risque de rehospitalisation. Des études complémentaires sont nécessaires pour évaluer la mortalité.
No takes yet. Share an insight, caveat, or question.
Okamba et al. (2026) conducted an observational in Heart failure (n=160). Sodium glucose cotransporter-2 inhibitors (SGLT-2i / gliflozins) vs. No SGLT-2i treatment was evaluated on Heart failure-related hospital readmission (3.6-fold increased risk of readmission for not receiving SGLT-2i, 95% CI 1.87-6.83, p=<0.001). SGLT-2i therapy in hospitalized HF patients was associated with lower readmission rates vs no SGLT-2i.
Synapse has enriched 10 related papers. Consider them for comparative context: